Dermata Therapeutics Announces Grant of Australian Patent for Innovative Hyperhidrosis Treatment

Reuters

07-08

Dermata <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Grant of Australian Patent for Innovative Hyperhidrosis Treatment

Dermata Therapeutics Inc. announced that the Australian Patent Office has granted a patent for its DMT410 program aimed at treating hyperhidrosis. The patent, titled "Compositions for the treatment of skin conditions," is a significant addition to Dermata's global intellectual property portfolio, reinforcing the company's commitment to innovative treatments for hyperhidrosis. This marks the second granted patent for DMT410, which utilizes Spongilla technology to deliver botulinum toxin topically. Dermata is also collaborating with Revance to study DMT410 for axillary hyperhidrosis, with potential applications for palmar and plantar hyperhidrosis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dermata Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1046453) on July 08, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2549544620"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2549544620\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2549544620?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-08 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2549544620","market":"nz","top_or_hot":-1,"title":"Dermata Therapeutics Announces Grant of Australian Patent for Innovative Hyperhidrosis Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Dermata <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Grant of Australian Patent for Innovative Hyperhidrosis Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/DRMA\">Dermata Therapeutics Inc</a>. announced that the Australian Patent Office has granted a patent for its DMT410 program aimed at treating hyperhidrosis. The patent, titled \"Compositions for the treatment of skin conditions,\" is a significant addition to Dermata's global intellectual property portfolio, reinforcing the company's commitment to innovative treatments for hyperhidrosis. This marks the second granted patent for DMT410, which utilizes Spongilla technology to deliver botulinum toxin topically. Dermata is also collaborating with Revance to study DMT410 for axillary hyperhidrosis, with potential applications for palmar and plantar hyperhidrosis.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dermata Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1046453) on July 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dermata Therapeutics Announces Grant of Australian Patent for Innovative Hyperhidrosis Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDermata Therapeutics Announces Grant of Australian Patent for Innovative Hyperhidrosis Treatment\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-07-08 20:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Dermata <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Grant of Australian Patent for Innovative Hyperhidrosis Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/DRMA\">Dermata Therapeutics Inc</a>. announced that the Australian Patent Office has granted a patent for its DMT410 program aimed at treating hyperhidrosis. The patent, titled \"Compositions for the treatment of skin conditions,\" is a significant addition to Dermata's global intellectual property portfolio, reinforcing the company's commitment to innovative treatments for hyperhidrosis. This marks the second granted patent for DMT410, which utilizes Spongilla technology to deliver botulinum toxin topically. Dermata is also collaborating with Revance to study DMT410 for axillary hyperhidrosis, with potential applications for palmar and plantar hyperhidrosis.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dermata Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1046453) on July 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250708:nNDLb3zG3H:1","article_id":"2549544620","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2549544620","pubTimestamp":1751976052,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Dermata Therapeutics Inc. announced that the Australian Patent Office has granted a patent for its DMT410 program aimed at treating hyperhidrosis. The patent, titled \"Compositions for the treatment of skin conditions,\" is a significant addition to Dermata's global intellectual property portfolio, reinforcing the company's commitment to innovative treatments for hyperhidrosis. This marks the second granted patent for DMT410, which utilizes Spongilla technology to deliver botulinum toxin topically. Dermata is also collaborating with Revance to study DMT410 for axillary hyperhidrosis, with potential applications for palmar and plantar hyperhidrosis.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dermata Therapeutics Inc. published the ori","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","BK4007":"制药","DRMA":"Dermata Therapeutics Inc","BK4139":"生物科技"},"translate_title":"Dermata Therapeutics宣布授予创新多汗症治疗澳大利亚专利","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DRMA":0.9},"content_text":"Dermata Therapeutics Announces Grant of Australian Patent for Innovative Hyperhidrosis Treatment\n    \n\nDermata Therapeutics Inc. announced that the Australian Patent Office has granted a patent for its DMT410 program aimed at treating hyperhidrosis. The patent, titled \"Compositions for the treatment of skin conditions,\" is a significant addition to Dermata's global intellectual property portfolio, reinforcing the company's commitment to innovative treatments for hyperhidrosis. This marks the second granted patent for DMT410, which utilizes Spongilla technology to deliver botulinum toxin topically. Dermata is also collaborating with Revance to study DMT410 for axillary hyperhidrosis, with potential applications for palmar and plantar hyperhidrosis.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dermata Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1046453) on July 08, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}